Literature DB >> 18081789

Clinical and pathologic prognostic factors in adult granulosa cell tumors of the ovary.

R Ranganath1, V Sridevi, S S Shirley, V Shantha.   

Abstract

The objective of this study was to determine the clinicopathologic prognostic factors in adult granulosa cell tumors of the ovary. A retrospective review of the records of patients of granulosa tumors who were treated at our institute over a period of 10 years (1995-2005) was done. Clinical, pathologic, and follow-up data were collected. A total of 34 patients who were treated during this period were subjected to analysis. Cox univariate analysis and Wilcoxon's test for multivariate analysis were used as part of the SPSS software for examining the data. It was found that optimal cytoreduction (P = 0.02), presence of nuclear atypia (P < 0.001), and increased mitoses (P = 0.03) were the three factors that impacted significantly on survival. Age, stage of the tumor, parity, and size of the tumor had no significant effect on survival. Patients who received chemotherapy had a better median disease-free survival than those who did not (60 vs 48 months), but this did not reach statistical significance (P = 0.08). Optimal cytoreduction, nuclear atypia, and increased mitoses are the statistically significant prognostic factors and may be used for selecting patients for adjuvant therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18081789     DOI: 10.1111/j.1525-1438.2007.01154.x

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  9 in total

1.  Ovarian Cancer in Young Women.

Authors:  Eileen Lalrinpuii; Pallipuram Seshadrinathan Bhageerathy; Ajit Sebastian; Lakshmanan Jeyaseelan; Anitha Thomas; Rachel Chandy; Abraham Peedicayil
Journal:  Indian J Surg Oncol       Date:  2017-07-21

Review 2.  Recent advances in granulosa cell tumor ovary: a review.

Authors:  Vijaykumar Dehannathparambil Kottarathil; Michelle Aline Antony; Indu R Nair; Keechilat Pavithran
Journal:  Indian J Surg Oncol       Date:  2012-12-07

Review 3.  Granulosa Cell Tumor of the Ovary: A Retrospective Study of 31 Cases and a Review of the Literature.

Authors:  Manel Dridi; Nesrine Chraiet; Rim Batti; Mouna Ayadi; Amina Mokrani; Khedija Meddeb; Yosra Yahiaoui; Henda Raies; Amel Mezlini
Journal:  Int J Surg Oncol       Date:  2018-03-29

4.  Adult Granulosa Cell Tumor: A Sinister Differential for Clomiphene-resistant Infertility.

Authors:  Shalini Gainder; Japleen Kaur; Sujata Siwatch; Nalini Gupta
Journal:  J Hum Reprod Sci       Date:  2018 Apr-Jun

5.  Meigs' syndrome caused by granulosa cell tumor accompanied with intrathoracic lesions: A case report.

Authors:  Xiao-Juan Wu; Hang-Biao Xia; Bao-Lin Jia; Gao-Wu Yan; Wen Luo; Yong Zhao; Xiao-Bin Luo
Journal:  World J Clin Cases       Date:  2021-06-26       Impact factor: 1.337

6.  Long-term follow-up is crucial after treatment for granulosa cell tumours of the ovary.

Authors:  G Mangili; J Ottolina; A Gadducci; G Giorda; E Breda; A Savarese; M Candiani; L Frigerio; G Scarfone; S Pignata; R Rossi; M Marinaccio; D Lorusso
Journal:  Br J Cancer       Date:  2013-06-11       Impact factor: 7.640

Review 7.  Gynecological cancers: A summary of published Indian data.

Authors:  Amita Maheshwari; Neha Kumar; Umesh Mahantshetty
Journal:  South Asian J Cancer       Date:  2016 Jul-Sep

8.  Adult Granulosa Cell Tumors of the Ovary: A Retrospective Study of 36 FIGO Stage I Cases with Emphasis on Prognostic Pathohistological Features.

Authors:  Emina Babarović; Ivan Franin; Marko Klarić; Ani Mihaljević Ferrari; Ružica Karnjuš-Begonja; Senija Eminović; Damjana Verša Ostojić; Danijela Vrdoljak-Mozetič
Journal:  Anal Cell Pathol (Amst)       Date:  2018-08-16       Impact factor: 2.916

9.  Ovarian granulosa cell tumor and clomiphene citrate resistance. A case report and review of the literature.

Authors:  Olga Triantafyllidou; George Sigalos; Irida Oikonomou; Nikos Vlahos
Journal:  JBRA Assist Reprod       Date:  2018-11-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.